Literature DB >> 2142403

Imaging of ovarian cancer with radiolabelled monoclonal antibodies.

D L van Kranenburg1, M J van Kroonenburgh, J B Trimbos, G J Fleuren, E K Pauwels.   

Abstract

This article presents the state of the art of immunoscintigraphy (IS) of ovarian cancer. We will review the monoclonal antibodies (MoAbs) used in clinical trials: (HMFG1/2, OC125, H317, H17E2, NDOG2 and 791T/36). We conclude that none of the afore mentioned MoAbs are clearly superior and that IS cannot yet replace laparotomy for the diagnosis of ovarian cancer but may have a role in the follow-up of ovarian cancer, in timing second-look surgery and assessing the response/TD treatment.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2142403     DOI： 10.1007/bf02390857

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN： 0932-0067            Impact factor:   2.344


  35 in total

1.  A reassessment of the role of second-look laparotomy in advanced ovarian cancer.

Authors:  A G Ho; U Beller; J L Speyer; N Colombo; J Wernz; E M Beckman
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

Review 2.  Prospects and applications of monoclonal antibodies in gynecological oncology.

Authors:  P Kenemans; R H Verheijen; A M Leloux; L G Poels
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1985-06       Impact factor: 2.435

3.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

4.  Radioimmunodetection in patients with suspected ovarian cancer.

Authors:  N Pateisky; K Philipp; W D Skodler; K Czerwenka; G Hamilton; J Burchell
Journal:  J Nucl Med       Date:  1985-12       Impact factor: 10.057

5.  Clinical implications for immunoscintigraphy in patients with ovarian malignancy: a preliminary study using monoclonal antibody 791T/36.

Authors:  E M Symonds; A C Perkins; M V Pimm; R W Baldwin; J G Hardy; D A Williams
Journal:  Br J Obstet Gynaecol       Date:  1985-03

6.  Radioimmunodiagnosis of ovarian cancer using 123I-labelled, tumor-associated monoclonal antibodies.

Authors:  A A Epenetos; J Shepherd; K E Britton; L Hawkins; C C Nimmon; J Taylor-Papadimitriou; H Durbin; J S Malpas; S Mather; M Granowska
Journal:  Cancer Detect Prev       Date:  1984

7.  The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer.

Authors:  J M Niloff; R C Knapp; P T Lavin; G D Malkasian; J S Berek; R Mortel; C Whitney; V R Zurawski; R C Bast
Journal:  Am J Obstet Gynecol       Date:  1986-07       Impact factor: 8.661

8.  Tumour-associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer.

Authors:  J H Shepherd; M Granowska; K E Britton; S Mather; A A Epenetos; B G Ward; M Slevin
Journal:  Br J Obstet Gynaecol       Date:  1987-02

9.  123I radioiodinated antibody imaging of occult ovarian cancer.

Authors:  A A Epenetos; J Shepherd; K E Britton; S Mather; J Taylor-Papadimitriou; M Granowska; H Durbin; C C Nimmon; L R Hawkins; J S Malpas
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

10.  Radionuclide imaging of epithelial ovarian tumours with 123I-labelled monoclonal antibody (H317) specific for placental-type alkaline phosphatase.

Authors:  M Critchley; S Brownless; M Patten; P J McLaughlin; P M Tromans; I W McDicken; P M Johnson
Journal:  Clin Radiol       Date:  1986-03       Impact factor: 2.350
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.